Table 1 of Tian, Mol Vis 2014; 20:1594-1604.


Table 1. Clinical features of patients with mutations in the BEST1 gene

Family Patient Age/
Gender Age at onset BCVA
(R,L) Fundus finding EOG Arden ratio ERG Genotype
A II:1 32Y/M 21Y 20/40
20/32 OD pseudohypopyon
OS vitelliruptive NA NA p.Q293H/+
B II:1 6Y/M 4Y 20/40
20/50 OU vitelliform lesion NA NA p.R218C/+
C I:1 36Y/M 30Y 20/50
20/50 OU pseudohypopyon OD 1.32
OS 1.25 Normal p.T4I/+
C II:1 10Y/F 9Y 20/40
20/40 OD pseudohypopyon
OS vitelliruptive OD 1.28
OS 1.30 Normal p.T4I/+
D II:1 45Y/M 42Y 20/40
20/32 OD pseudohypopyon
OS vitelliform lesion OD 1.34
OS 1.21 Normal p.D301G/+
E II:1 58Y/F 50Y 20/32
20/100 OU pseudohypopyon NA NA p.A291V/+
F III:1 26Y/ M 25Y 20/32
20/40 OU pseudohypopyon NA NA p.R218C/+
G II:1 6Y/M 5Y 20/200
20/63 OD subretinal fibrosisi
OS subretinal fibrosisi; yellowish deposits OD 0.95
OS 1.18 Reduced scotopic and photopic
responses p.M163R/p.M163R
H II:1 26Y/M 23Y 20/63
20/200 OU yellowish deposits OD 1.11
OS 1.23 Reduced scotopic and photopic
responses p.R130L/p.R130L
I II:1 11Y/M 8Y 20/32
20/32 OU macular scar NA NA c.519delA/p.W287*
J II:2 11Y/F 9Y 20/200
20/40 OD macular scar
OS vitelliruptive NA NA p.Y33H/p.R255W
K II:2 15Y/M 11Y 20/63
20/400 OU hyperpigmented
scar OD 1.20
OS 1.32 Normal p.R13H/p.A195V
L II:1 25Y 22Y 20/50
20/40 OD pseudohypopyon
OS vitelliform lesion NA NA p.A195V/p.R255W